Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Explored for combined amylin + GLP-1 signaling Researchers study whether pairing an amylin analog with a GLP-1 agonist adds to appetite-pathway effects beyond either component alone
That positioning places MOTS-c alongside compounds such as SS-31 in mitochondrial research programs, though the two act through separate pathways
Lipotropic injections contain weight-loss supporting nutrients like B vitamins, carnitine, choline, and inositol
The mechanism is thought to relate to glucagon-receptor activation and energy-substrate shifts, but it is not fully characterized
While these can help, they often fall short for those with persistent gut issues, especially when tissue damage is involved
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
US$ 21.75
US$ 23.92
US$ 24.90
US$ 28.11
US$ 29.23
